QuantLogix ← VRTX scorecard
📅 VRTX Earnings Preview
Vertex Pharmaceuticals Inc
Next report (est.)
11/25/2026
Countdown
77 days
EPS growth YoY
+8.0%
Revenue growth YoY
+12.5%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
08/04/2026 ±2.8% +1.7% over-priced
05/05/2026 ±1.8% -1.3% over-priced
11/04/2025 ±2.0% -1.0% over-priced
08/05/2025 ±2.3% -20.6% under-priced
05/06/2025 ±2.4% -10.0% under-priced
11/05/2024 ±1.9% +5.7% under-priced
08/02/2024 ±2.1% -2.2% under-priced
05/07/2024 ±2.0% +1.9% over-priced
Across these reports, options implied an average ±2.1% move vs an actual average of 5.6% — the stock stayed inside the implied band 50% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $4.31 $3.3B $1.1B
Q1 FY2026 $4.02 $3.0B $1.0B
Q4 FY2025 $4.64 $3.2B $1.2B
Q3 FY2025 $4.20 $3.1B $1.1B
Analyst posture
Buy / Strong Buy
29
Hold
6
Sell
1
Downward revisions — 38 net (vs 39 prior)
Live 5-factor engine read: Strong Buy · 60/100 Full scorecard →
Get alerted before every VRTX report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on VRTX before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Vertex Pharmaceuticals Inc (VRTX) reports in 77 days, with the next report estimated for 11/25/2026. Across the last 8 reports, options priced an average ±2.1% earnings move while the stock actually moved 5.6% on average — the market has been roughly fair on VRTX's earnings risk. Fundamentals into the print: EPS up 8.0% year-over-year, revenue up 12.5%. QuantLogix's live 5-factor engine currently reads VRTX as a strong buy at 60/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →